The Ruby Study and the NRG Study on Endometrial Cancer

We're learning a lot about the molecular characteristics of these cancers. We have an estrogen positive population and hormone therapy has been shown here to be active as a target. When did when to treat on the hormone path, when to treat with the addition of let chazol and anvilymus is up for debate still. And you see that P53 group really doing the worst, and that'll come back as we talk about this.